Investors considering a purchase of BioCryst Pharmaceuticals, Inc. (BCRX - Get Report) stock, but tentative about paying the going market price of $5.21/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2019 put at the $3 strike, which has a bid at the time of this writing of 32 cents. Collecting that bid as the premium represents a 10.7% return against the $3 commitment, or a 8.4% annualized rate of return (at Stock Options Channel we call this the YieldBoost).Selling a put does not give an investor access to BCRX's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $3 strike if doing so produced a better outcome than selling at the going market price. ( Do options carry counterparty risk? This and six other common options myths debunked). So unless BioCryst Pharmaceuticals, Inc. sees its shares fall 41.8% and the contract is exercised (resulting in a cost basis of $2.68 per share before broker commissions, subtracting the 32 cents from $3), the only upside to the put seller is from collecting that premium for the 8.4% annualized rate of return. Below is a chart showing the trailing twelve month trading history for BioCryst Pharmaceuticals, Inc., and highlighting in green where the $3 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the January 2019 put at the $3 strike for the 8.4% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for BioCryst Pharmaceuticals, Inc. (considering the last 253 trading day closing values as well as today's price of $5.21) to be 73%. For other put options contract ideas at the various different available expirations, visit the BCRX Stock Options page of StockOptionsChannel.com.
More from Stocks
What to Watch When Snap Reports Its Latest Results
Snap's user trends have stabilized, and its revenue has grown this year. Can it keep up the pace?
Acadia Falls Sharply in After-Hours Trading After Schizophrenia Drug Fails Study
Stock drops as Pimavanserin study finds no statistically significant improvement in adult schizophrenia patients.
A Slow Tape Means Investors Need to Find Other Things to Do
When the tape slows down it's a dangerous time to be trading.